Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney disease
Biotech
Vertex races to FDA after phase 3 kidney disease data impress
The phase 3 win for povetacicept met analyst expectations and fired the starting gun on a race to the FDA that could result in a November approval.
Nick Paul Taylor
Mar 10, 2026 6:20am
Lilly pays CSL $100M for IL-6 drug that flunked transplant study
Feb 18, 2026 5:07am
Boehringer channels midstage momentum into pivotal kidney trial
Jan 28, 2026 5:39am
Boehringer continues kidney dealmaking with $120M Variant pact
Jan 6, 2026 10:45am
Akebia promises $12M for Q32’s rare kidney disease candidate
Dec 1, 2025 9:45pm
Biogen returns to its roots with a West Coast immunology outpost
Nov 18, 2025 12:25pm
